• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Compulsive Biting and Chewing with Mixed Amphetamine Salts: A Case Report.混合苯丙胺盐所致强迫性咬嚼行为:一例报告
Innov Clin Neurosci. 2024 Jun 1;21(4-6):11-13. eCollection 2024 Apr-Jun.
2
Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.混合安非他明盐缓释剂(阿得拉XR)治疗青少年注意缺陷多动障碍的疗效与安全性:一项为期4周的随机、双盲、安慰剂对照平行组研究。
Clin Ther. 2006 Feb;28(2):266-79. doi: 10.1016/j.clinthera.2006.02.011.
3
Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.SHP465混合苯丙胺盐治疗成人注意力缺陷/多动障碍的疗效与安全性:一项随机、双盲、安慰剂对照、强制剂量临床研究的结果
CNS Drugs. 2017 Aug;31(8):685-697. doi: 10.1007/s40263-017-0455-7.
4
A Phase 3, Randomized Double-Blind Study of the Efficacy and Safety of Low-Dose SHP465 Mixed Amphetamine Salts Extended-Release in Children with Attention-Deficit/Hyperactivity Disorder.一项评估低剂量 SHP465 混合安非他命硫酸盐缓释剂治疗注意缺陷多动障碍(ADHD)儿童的有效性和安全性的 3 期、随机、双盲研究。
J Child Adolesc Psychopharmacol. 2020 Nov;30(9):549-557. doi: 10.1089/cap.2020.0005. Epub 2020 Oct 13.
5
Clinical effects of lisdexamfetamine and mixed amphetamine salts immediate release in adult ADHD: results of a crossover design clinical trial.赖氨酸安非他明和速释混合苯丙胺盐治疗成人注意力缺陷多动障碍的临床效果:一项交叉设计临床试验的结果
Postgrad Med. 2014 Sep;126(5):17-24. doi: 10.3810/pgm.2014.09.2796.
6
SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results of a Randomized, Double-Blind Placebo-Controlled Study.SHP465混合苯丙胺盐治疗儿童和青少年注意力缺陷/多动障碍:一项随机、双盲、安慰剂对照研究的结果。
J Child Adolesc Psychopharmacol. 2018 Feb;28(1):19-28. doi: 10.1089/cap.2017.0053. Epub 2017 Aug 17.
7
A randomized, double-blind, 3-way crossover, analog classroom study of SHP465 mixed amphetamine salts extended-release in adolescents with ADHD.一项关于 SHP465 混合安非他命硫酸盐缓释剂在 ADHD 青少年中应用的随机、双盲、三向交叉、模拟课堂研究。
Postgrad Med. 2019 Apr;131(3):212-224. doi: 10.1080/00325481.2019.1574402. Epub 2019 Feb 18.
8
A randomized, double-blind study of SHP465 mixed amphetamine salts extended-release in adults with ADHD using a simulated adult workplace design.一项使用模拟成人工作场所设计的、评估 SHP465 混合安非他命盐长效片治疗成人 ADHD 的随机、双盲研究。
Postgrad Med. 2018 Jun;130(5):481-493. doi: 10.1080/00325481.2018.1481712. Epub 2018 Jun 18.
9
Responder and Remission Analyses from Two Studies of SHP465 Mixed Amphetamine Salts Extended-Release Among Adults with Attention-Deficit/Hyperactivity Disorder.两项 SHP465 混合安非他命盐长效治疗成人注意缺陷多动障碍应答和缓解分析研究
J Child Adolesc Psychopharmacol. 2020 Sep;30(7):427-438. doi: 10.1089/cap.2020.0012. Epub 2020 May 19.
10
Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults.用于治疗成人注意力缺陷多动障碍(ADHD)的苯丙胺类药物。
Cochrane Database Syst Rev. 2018 Aug 9;8(8):CD007813. doi: 10.1002/14651858.CD007813.pub3.

引用本文的文献

1
Response to "Before Attributing Compulsive Chewing to Amphetamines, Alternative Causes Must Be Thoroughly Ruled Out".对《在将强迫性咀嚼归因于苯丙胺之前,必须彻底排除其他原因》的回应
Innov Clin Neurosci. 2025 Jun 1;22(4-6):11-12. eCollection 2025 Apr-Jun.
2
Before Attributing Compulsive Chewing to Amphetamines, Alternative Causes Must Be Thoroughly Ruled Out.在将强迫性咀嚼归因于安非他明之前,必须彻底排除其他可能的原因。
Innov Clin Neurosci. 2025 Jun 1;22(4-6):11. eCollection 2025 Apr-Jun.

本文引用的文献

1
The Practical Importance of Half-Life in Psychopharmacology.精神药理学中半衰期的实际重要性。
J Clin Psychiatry. 2022 Jul 25;83(4):22f14584. doi: 10.4088/JCP.22f14584.
2
ADHD and Bipolar Disorder in Adulthood: Clinical and Treatment Implications.成人注意缺陷多动障碍与双相障碍:临床与治疗意义。
Medicina (Kaunas). 2021 May 10;57(5):466. doi: 10.3390/medicina57050466.
3
The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis.成人注意缺陷多动障碍的患病率:全球系统评价和荟萃分析。
J Glob Health. 2021 Feb 11;11:04009. doi: 10.7189/jogh.11.04009.
4
Comorbidity of ADHD and adult bipolar disorder: A systematic review and meta-analysis.注意缺陷多动障碍与成人双相情感障碍的共病:一项系统评价和荟萃分析。
Neurosci Biobehav Rev. 2021 May;124:100-123. doi: 10.1016/j.neubiorev.2021.01.017. Epub 2021 Jan 27.
5
The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.安非他命和哌甲酯的药理学:与注意力缺陷多动障碍和其他精神共病的神经生物学相关性。
Neurosci Biobehav Rev. 2018 Apr;87:255-270. doi: 10.1016/j.neubiorev.2018.02.001. Epub 2018 Feb 8.
6
Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.SHP465混合苯丙胺盐治疗成人注意力缺陷/多动障碍的疗效与安全性:一项随机、双盲、安慰剂对照、强制剂量临床研究的结果
CNS Drugs. 2017 Aug;31(8):685-697. doi: 10.1007/s40263-017-0455-7.
7
The Risk of Treatment-Emergent Mania With Methylphenidate in Bipolar Disorder.双相情感障碍患者使用哌甲酯后出现治疗中躁狂发作的风险
Am J Psychiatry. 2017 Apr 1;174(4):341-348. doi: 10.1176/appi.ajp.2016.16040467. Epub 2016 Oct 3.
8
Adult ADHD: A new disease?成人注意力缺陷多动障碍:一种新疾病?
Int J Psychiatry Clin Pract. 2016;20(2):70-6. doi: 10.3109/13651501.2016.1149197. Epub 2016 Apr 7.
9
A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment.系统回顾和分析注意缺陷多动障碍的长期结局:治疗和非治疗的影响。
BMC Med. 2012 Sep 4;10:99. doi: 10.1186/1741-7015-10-99.
10
The neurobiology of the switch process in bipolar disorder: a review.双相障碍转换过程的神经生物学:综述。
J Clin Psychiatry. 2010 Nov;71(11):1488-501. doi: 10.4088/JCP.09r05259gre. Epub 2010 May 4.

混合苯丙胺盐所致强迫性咬嚼行为:一例报告

Compulsive Biting and Chewing with Mixed Amphetamine Salts: A Case Report.

作者信息

Free Melissa, Choi Hena, Baweja Ritika

机构信息

Drs. Free and Baweja are with Department of Psychiatry and Behavioral Health, Penn State Health Milton S. Hershey Medical Center in Hershey, Pennsylvania.

Ms. Choi is with Penn State College of Medicine in Hershey, Pennsylvania.

出版信息

Innov Clin Neurosci. 2024 Jun 1;21(4-6):11-13. eCollection 2024 Apr-Jun.

PMID:38938532
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11208004/
Abstract

Stimulants are the first-line pharmacological treatment for attention deficit hyperactivity disorder (ADHD). We present the unique case of a patient who developed a chewing compulsion when taking mixed amphetamine salts (MAS). A 32-year-old female patient with a past medical history of gastroesophageal reflux disease (GERD), gastroparesis, and migraines was seen for initial psychiatric assessment due to concerns for irritability. She was diagnosed with post-traumatic stress disorder (PTSD); generalized anxiety disorder; ADHD, inattentive type; and unspecified bipolar disorder. Lamotrigine was started and titrated to 25mg twice per day, with improved mood stability. MAS immediate-release (IR) was started at 2.5mg and titrated to 5mg daily for ADHD. She then experienced an uncontrollable urge to chew, finding relief when chewing on a child's teething necklace, which provided satisfaction and a reduction in anxiety. She denied jaw tightness or teeth grinding. The dose of MAS IR was reduced to 2.5mg daily with improvement in symptoms and later increased again to 5mg daily, which she was then able to tolerate. Stereotyped biting behaviors have been observed in rats with the use of amphetamines, and the onset of compulsive behavior has emerged in children with the use of dextroamphetamine. However, this is the first known case of compulsive chewing or biting movements reported in humans with MAS use. This case highlights the need to assess patients for adverse events, such as compulsive biting and chewing movements or other oral facial stereotypies, after commencement of stimulants, including MAS.

摘要

兴奋剂是治疗注意力缺陷多动障碍(ADHD)的一线药物治疗方法。我们报告了一例独特的病例,一名患者在服用混合苯丙胺盐(MAS)时出现了咀嚼强迫行为。一名32岁女性患者,既往有胃食管反流病(GERD)、胃轻瘫和偏头痛病史,因易怒问题前来进行初次精神科评估。她被诊断为创伤后应激障碍(PTSD)、广泛性焦虑障碍、注意力不集中型ADHD和未特定的双相情感障碍。开始使用拉莫三嗪并滴定至每日两次,每次25mg,情绪稳定性有所改善。开始使用MAS速释片(IR),起始剂量为2.5mg,滴定至每日5mg用于治疗ADHD。随后,她经历了无法控制的咀嚼冲动,在咀嚼儿童出牙项链时能得到缓解,这能带来满足感并减轻焦虑。她否认有牙关紧闭或磨牙现象。MAS IR的剂量减至每日2.5mg后症状有所改善,后来又增至每日5mg,此时她能够耐受。在使用苯丙胺的大鼠中观察到了刻板的咬啮行为,在使用右旋苯丙胺的儿童中出现了强迫行为发作。然而,这是已知首例在使用MAS的人类中报告的强迫性咀嚼或咬啮动作病例。该病例强调了在开始使用包括MAS在内的兴奋剂后,需要评估患者是否出现不良事件,如强迫性咬啮和咀嚼动作或其他口面部刻板行为。